HONG KONG – Generon Corp. (Shanghai) Ltd. has reached an agreement with the FDA under a special protocol assessment (SPA) regarding the second pivotal global phase III study design of its chemotherapy-induced neutropenia (CIN) treatment.

HONG KONG – YL Biologics Ltd. has inked a licensing deal to distribute a biosimilar for the treatment of anemia by Korea’s CJ Healthcare Ltd. in Japan. The drug, CJ-40001, is CJ Healthcare’s version of Amgen Inc.’s Aranesp (darbepoetin alfa).

HONG KONG – Chinese biotech company Hybio Pharmaceutical Co. recently received approval from the CFDA to conduct clinical trials for its generic version of GLP-1 analogue liraglutide.

HONG KONG Abbvie Inc. has added a biologics manufacturing unit in its Singapore plant, to ensure sufficient supply of biomedicines and perfect the ecosystem of biologics innovation in the region.

HONG KONG Abbvie Inc. has added a biologics manufacturing unit in its Singapore plant, to ensure sufficient supply of biomedicines and perfect the ecosystem of biologics innovation in the region.

HONG KONG – Merck KGaA has just opened its first Asian end-to-end drug development center in Shanghai.